Avanos Medical, Inc. (NYSE:AVNS) Receives Consensus Rating of “Hold” from Brokerages

Avanos Medical, Inc. (NYSE:AVNS – Get Rating) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $38.75.

Several research analysts recently issued reports on AVNS shares. Zacks Investment Research lowered Avanos Medical from a “strong-buy” rating to a “hold” rating and set a $33.00 target price for the company. in a research report on Tuesday, April 26th. StockNews.com lowered Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 16th. Finally, KeyCorp lowered their target price on Avanos Medical from $47.00 to $41.00 and set an “overweight” rating for the company in a research report on Thursday, February 24th.

Several hedge funds have recently bought and sold shares of the company. Farmers & Merchants Investments Inc. bought a new stake in Avanos Medical in the 1st quarter valued at about $30,000. First Quadrant L P CA bought a new stake in Avanos Medical in the 4th quarter valued at about $41,000. First Horizon Advisors Inc. increased its position in Avanos Medical by 5,095.7% in the 4th quarter. First Horizon Advisors Inc. now owns 1,195 shares of the company’s stock valued at $41,000 after buying an additional 1,172 shares in the last quarter. KBC Group NV bought a new stake in Avanos Medical in the 3rd quarter valued at about $48,000. Finally, UMB Bank N A MO bought a new stake in Avanos Medical in the 4th quarter valued at about $79,000. 92.71% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE AVNS traded down $0.37 during mid-day trading on Friday, hitting $27.60. 197,407 shares of the stock traded hands, compared to its average volume of 326,217. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.87 and a quick ratio of 1.84. Avanos Medical has a twelve month low of $24.84 and a twelve month high of $40.81. The company has a market cap of $1.31 billion, a PE ratio of 72.63 and a beta of 0.87. The firm has a 50 day simple moving average of $30.88 and a two-hundred day simple moving average of $31.77.

Avanos Medical (NYSE:AVNS – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Avanos Medical had a return on equity of 4.49% and a net margin of 2.44%. The company had revenue of $197.40 million for the quarter, compared to the consensus estimate of $197.80 million. During the same quarter last year, the business posted $0.23 EPS. Avanos Medical’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, equities research analysts anticipate that Avanos Medical will post 1.66 earnings per share for the current fiscal year.

About Avanos Medical (Get Rating)

Avanos Medical, Inc, a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands.

Featured Articles